Vanguard Capital Management
OBIO icon

Vanguard Capital Management’s Orchestra BioMed OBIO Stock Holding History

Vanguard Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.73M Sell
2,022,916
-181,403
-8% -$742K ﹤0.01% 2904
2026
Q1 		$9.37M Buy
+2,204,319
New +$9.38M ﹤0.01% 2765

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Capital Management's OBIO Position: Q2 2026 in Review

Vanguard Capital Management reduced its Orchestra BioMed (OBIO) stake by 8.2% in Q2 2026, selling an estimated $742K and leaving 2,022,916 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Vanguard Capital Management first reported a position in OBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.37M in Q1 2026. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Vanguard Capital Management held 2,022,916 shares of Orchestra BioMed worth $8.73M as of Q2 2026.
  • Vanguard Capital Management sold 181,403 Orchestra BioMed shares in Q2 2026, an estimated $742K.
  • Orchestra BioMed made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2904 holding.
  • Vanguard Capital Management first reported a position in Orchestra BioMed in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Orchestra BioMed position peaked at $9.37M in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.